Journal of Hepatology
Volume 47, Issue 4 , Pages 506-513 , October 2007

Oral contraception and the risk of hepatocellular carcinoma

Received 6 October 2006 ,Revised 22 February 2007 ,Accepted 13 March 2007.

References 

  1. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001;5:87–107
  2. Villa E, Melegari M, Scaglioni PP, Trande P, Cesaro P, Manenti F. Hepatocellular carcinoma: risk factors other than HBV. Ital J Gastroenterol. 1991;23:457–460
  3. Yu MC, Yuan J. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004;127:72–78
  4. Kojima H, Sakurai S, Matsumara M, Umemoto N, Uemura M, Morimoto H, et al. Cryptogenic cirrhosis in the region where obesity is not prevalent. World J Gastroenterol. 2006;12:2080–2085
  5. Lindberg MC. Hepatobiliary complications of oral contraceptives. J Gen Intern Med. 1992;7:199–209
  6. Benedetti V, Welsh J, Yu M, Bennett W. p53 mutations in hepatocellular carcinoma related to oral contraceptive use. Carcinogenesis. 1996;17:145–149
  7. Mays ET, Christopherson W. Hepatic tumors induced by sex steroids. Sem Liver Dis. 1984;4:147–157
  8. Korula J, Yellin A, Kanel G, Campofiori G, Nichols P. Hepatocellular carcinoma coexisting with hepatic adenoma: incidental discovery after long-term oral contraceptive use. Western J Med. 1991;155:416–418
  9. Kenya PR. Oral contraceptives use and liver tumours: a review. East Afr Med J. 1990;67:146–153
  10. Rosenberg L. The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception. 1991;43:643–652
  11. Heinemann LAJ, DoMinh T, Guggenmoos-Holzmann I, Thiel C, Garbe E. Oral contraceptives and liver cancer: results of the multicentre international liver tumor study (MILTS). Contraception. 1997;56:275–284
  12. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J. 1986;292:1355–1357
  13. Henderson BE, Preston-Martin S, Edmondson HA, Peters RL, Pike MC. Hepatocellular carcinoma and oral contraceptives. Br J Cancer. 1983;48:437–440
  14. Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C. Female hormone utilization and risk of hepatocellular carcinoma. Br J Cancer. 1993;67:635–637
  15. Hsing AW, Hoover RN, McLaughlin JK, Co-Chien H, Wacholder S, Blot W, et al. Oral contraceptives and primary liver cancer among young women. Cancer Causes Controls. 1992;3:43–48
  16. Forman D, Vincent TJ, Doll R. Cancer of the liver and the use of oral contraceptives. Br Med J. 1986;292:1357–1361
  17. Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S. Oral contraceptive use and liver cancer. Am J Epidemiol. 1989;130:878–882
  18. Kew M, Song E, Mohammed A, Hodkinson J. Contraceptive steroids as a risk factor for hepatocellular carcinoma: a case/control study in south african black women. Hepatology. 1990;11:298–302
  19. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Combined oral contraceptives and liver cancer. Int J Cancer 1989;43:254–259.
  20. La Vecchia C, Negri E, Parazzini F. Oral contraceptives and primary liver cancer. Br J Cancer. 1989;59:460–461
  21. Vall Mayans M, Calvet X, Bruix J, Bruguera M, Costa J, Esteve J, et al. Risk factors for hepatocellular carcinoma in Catalonia, Spain. Int J Cancer. 1990;46:378–381
  22. Yu MC, Tong MJ, Govindarahan S, Henderson BE. Non-viral risk factors for hepatocellular carcinoma in a low risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst. 1991;83:1820–1826
  23. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;6:676–680
  24. STATA. Statistical software package, version 8. College Station, Texas: Stata Press.
  25. El-Serag H, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of the epidemiological evidence. Clin Gastroenterol Hepatol. 2006;3:369–380
  26. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?. Stat Med. 2002;21:1559–1573

☆ None of the authors has any potential conflict of interest with the study. There is no funding agency for the study. Dr. El-Serag acknowledges support of Digestive Disease Center (PHS grant 56338).

PII: S0168-8278(07)00193-6

doi: 10.1016/j.jhep.2007.03.015

Journal of Hepatology
Volume 47, Issue 4 , Pages 506-513 , October 2007

Article Tools

* Image Usage & Resolution